ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO833

Dietary N-3 Polyunsaturated Fatty Acids (PUFA) Intake and Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular


  • Saglimbene, Valeria Maria, University of Sydney, Sydney, Australia
  • Wong, Germaine, University of Sydney, Sydney, New South Wales, Australia
  • Craig, Jonathan C., University of Sydney/Children's Hospital, Sydney, New South Wales, Australia
  • Hegbrant, Jorgen BA, Diaverum Medical-Scientific Office, Lund, Sweden
  • Strippoli, Giovanni F.M., University of Bari, Bari, Italy
  • Ruospo, Marinella, Diaverum, Bari, Italy

Group or Team Name

  • For DIET-HD investigators

N-3 PUFA are protective factors for cardiovascular risk in the general population. However their role in hemodialysis patients, in whom the pathogenesis of cardiovascular disease is different, is uncertain.


The DIET-HD study is a prospective cohort study (January 2014-January 2016) in 9757 adults treated with hemodialysis in Europe and South America. The dietary N-3 PUFA intake was measured at baseline using the validated GA2LEN Food Frequency Questionnaire. Adjusted cox regression analyses clustered by country were conducted to evaluate the association between dietary N-3 PUFA intake and cardiovascular and all-cause mortality.


During a median follow up of 1.5 years (8108 person-years), there were 1214 deaths of which 515 were attributable to cardiovascular causes. Compared to patients with the lowest dietary N-3 PUFA intake (<0.37 g/wk), the hazard ratios (95% confidence intervals) for cardiovascular mortality among patients in the middle (0.37 to <1.8 g/wk) and highest (≥1.8 g/wk) tertiles of N-3 PUFA were 0.80 (0.64 to 1.00) and 1.13 (0.88 to 1.45), respectively; the hazard ratios for all-cause mortality were 0.95 (0.82 to 1.09) and 1.08 (0.92 to 1.28), respectively. Only one third of the study population consumed sufficient N-3 PUFA (at least 1.75 g/wk) as recommended for primary cardiovascular prevention, and less than 10% as recommended for secondary prevention (7-14 g/wk).


Dietary N-3 PUFA intake was not associated with cardiovascular or all-cause mortality in patients on hemodialysis. The possibility that higher dose N-3 PUFA, reached from supplementation, might mitigate cardiovascular risk has not been excluded.